Key Highlights

  • Akari and Whitehawk Therapeutics will run joint preclinical studies pairing Akari's PH1 spliceosome-modulating payload with Whitehawk's TOP1i ADC platform; no financial terms or clinical assets were disclosed in the July 21, 2026 announcement.
  • Lead candidate AKTX-101 remains in IND-enabling studies targeting a Phase 1 first-in-human trial by mid-2027; a second candidate, AKTX-102, targeting CEACAM5, is also still in preclinical development.
  • Akari's cash balance of $2.8 million at March 31, 2026, triggered an explicit going-concern disclosure, though a $5.5 million private placement and $2.8 million of warrant exercises brought in roughly $8.3 million during the second quarter of 2026.
  • Akari Therapeutics has spent two years transforming from a complement-inhibitor developer into an ADC company built around one bet: disrupting RNA splicing inside cancer cells can outperform the microtubule- and DNA-damaging payloads used in approved ADCs today.

Akari Therapeutics, Plc (NASDAQ:AKTX) has entered a preclinical research collaboration with Whitehawk Therapeutics to test whether its RNA-splicing payload, PH1, can be combined with Whitehawk's topoisomerase I inhibitor ADC platform. Announced July 21, 2026, the deal arrives as Akari pushes its lead candidate, AKTX-101, toward a targeted mid-2027 first-in-human trial while carrying just $2.8 million in cash and a going-concern warning in its latest quarterly filing.

A Small-Cap Oncology Story Looks for a New Catalyst

Akari Therapeutics has spent two years transforming from a complement-inhibitor developer into an ADC company built around one bet: disrupting RNA splicing inside cancer cells can outperform the microtubule- and DNA-damaging payloads used in approved ADCs today. That bet took a new turn on July 21, 2026, when Akari announced a research collaboration with Whitehawk Therapeutics, a clinical-stage ADC developer, to evaluate combining Akari's proprietary PH1 payload with Whitehawk's topoisomerase I inhibitor (TOP1i) platform. The announcement, and a follow-up CEO interview published July 22, 2026, frame the tie-up as validation of Akari's payload science rather than a near-term revenue event, watched closely by investors gauging whether the pipeline can reach clinical proof-of-concept after a Nasdaq bid-price scare earlier this year.

From Complement Biology to a Splicing-Focused ADC Platform

Akari Therapeutics is a United Kingdom-incorporated public limited company whose American Depositary Shares trade on the Nasdaq Capital Market under the ticker AKTX. The company files as a U.S. domestic filer on Forms 10-K and 10-Q rather than the 20-F used by many foreign private issuers; its most recent annual report was filed with the SEC on March 30, 2026, for the year ended December 31, 2025.

Historically, Akari developed nomacopan, a complement C5 and leukotriene B4 inhibitor, alongside PAS-nomacopan and PHP-303, a neutrophil elastase inhibitor licensed from Bayer in 2017. Following its November 14, 2024 acquisition of Peak Bio, Inc., which brought ADC discovery capabilities and assumed notes and warrants, Akari redirected toward oncology. Its March 2026 Form 10-K designates nomacopan, PAS-nomacopan and PHP-303 as "legacy programs" that are "not part of our active portfolio," for which management seeks out-licensing partners. The active pipeline centers on AKTX-101, a Trop2-targeting ADC, and AKTX-102, targeting CEACAM5, both built on the PH1 payload and a non-cleavable linker.

Whitehawk Collaboration Adds a Second Voice to Akari's (AKTX) Payload Story

Under the July 21, 2026 agreement, Akari will lead design and execution of preclinical workstreams evaluating dual-payload compatibility between PH1 and Whitehawk's TOP1i platform, itself built on technology in-licensed from WuXi Biologics and Hangzhou DAC. The companies described the work as generating data to "guide future development decisions and potential broader collaboration opportunities." The release disclosed no upfront payments, milestones or equity terms; both sides called it evaluation-stage. Akari CEO Abizer Gaslightwala called it "an important first step in exploring the broader potential of our PH1 payload technology," while Whitehawk CEO Dave Lennon framed it as testing whether combining differentiated mechanisms could support future development. This is explicitly preclinical work; no dual-payload candidate has entered human testing.

First-Quarter Results Show a Cash Squeeze and Non-Cash Impairments

In its Form 10-Q filed May 19, 2026, for the quarter ended March 31, 2026, Akari reported cash of $2.8 million, down from $5.2 million at December 31, 2025, against total assets of $33.9 million and total liabilities of $19.5 million. Shareholders' equity fell to $14.4 million from $28.3 million. Net loss widened to $14.5 million from $3.7 million a year earlier, driven mostly by non-cash charges: an $8.4 million impairment that fully wrote off goodwill and a $3.7 million impairment against the AKTX-101 intangible asset, both triggered by "a sustained decline in the Company's ADS price and market capitalization." R&D expense rose to $1.5 million from $0.8 million, while G&A eased to $2.2 million from $2.7 million.

Liquidity, Going Concern and a Post-Quarter Capital Infusion

The filing disclosed an accumulated deficit of $279.0 million and stated the cash balance "is not sufficient to fund its operations for the one-year period after the date these condensed consolidated financial statements are issued," raising "substantial doubt about the Company's ability to continue as a going concern." Funding has since materialized: on June 29, 2026, Akari confirmed roughly $8.3 million received in the second quarter, comprising a $5.5 million private placement priced May 21, 2026 and $2.8 million from May warrant exercises. The PIPE's final tranche closed early, on June 26, 2026.

Nasdaq Compliance, the ADS Ratio Change and What Comes Next

On November 24, 2025, Nasdaq notified Akari that its ADSs had traded below the $1.00 minimum bid price for 30 consecutive business days, setting a compliance deadline of May 25, 2026. Rather than a reverse split, Akari changed its ADS-to-ordinary-share ratio effective March 31, 2026, from one ADS representing 2,000 ordinary shares to one representing 80,000 shares; Nasdaq confirmed the company had regained compliance. Akari began GMP manufacturing with WuXi Biologics/XDC in December 2025 to support a targeted mid-2027 Phase 1 start for AKTX-101. A May 21, 2026 ASCO abstract reported preclinical synergy between AKTX-101 and the approved KRAS inhibitor adagrasib in KRAS-mutant pancreatic cancer models, a signal the company cites for applicability beyond Trop2.

Weighing the Risks Specific to Akari's Position

Akari's risks are concentrated. The going-concern language reflects a cash position that, absent the subsequent PIPE and warrant proceeds, would not have covered a few months of expenses at the current burn rate. The company has no product candidate in human trials, so every efficacy claim rests on preclinical data that may not translate clinically. Dilution is persistent: outstanding ordinary shares rose from roughly 90.5 billion to 91.6 billion in one quarter, and antidilutive securities excluded from loss-per-share totaled more than 121 billion shares at March 31, 2026. The Whitehawk tie-up carries execution risk as an evaluation-stage arrangement with no guaranteed path to a joint asset.

Outlook

In an upside case, positive IND-enabling data, a clean Phase 1 start by mid-2027, and continued validation from partners such as Whitehawk could support Akari's thesis that PH1 is a genuinely differentiated payload class. In a base case, Akari keeps funding operations quarter to quarter through placements and shelf registrations while advancing AKTX-101 on its current timeline, with dilution a persistent drag on per-share value. In a downside case, further cash shortfalls or disappointing data could delay the Phase 1 program or renew listing pressure. None of this should be read as a forecast of share-price direction; it describes operational trajectories only.

Conclusion

Akari Therapeutics, Plc (AKTX) has used its Whitehawk Therapeutics collaboration to reinforce a narrative that its PH1 RNA-splicing payload deserves a place in next-generation ADC development. That narrative is credible as far as the preclinical data goes, but AKTX-101 remains a preclinical-to-IND-stage asset, the company disclosed a going-concern doubt in its latest filing, and its ADS price required a ratio adjustment to stay listed on Nasdaq. Investors weighing AKTX should track both the science and the balance sheet.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.